Category Archives: Patent Eligible Subject Matter

Section 101 at the AIPLA Midwinter Meeting

Posted on February 2, 2015 by Warren Woessner

Although the primary focus of this four day meeting was licensing, there were two simultaneous tracks that contained at least a section of the effect/uncertainty of the recent judicial decisions and PTO Guidelines on licensor/licensee relationships. (I spoke at one … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , | Leave a comment

Myriad Settles – Questions Remain

Posted on January 27, 2015 by Warren Woessner

Yesterday, Myriad announced it has settled the BRCA assay litigations that had been ongoing—and not going well– with Pathway Genomics, Invitae and Gene by Gene (and I assume….Ambry and Labcorp). Although I was just about at the brink of shouting … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , | Leave a comment

The “Top Ten” IP Stories of 2014 (Most “Definitely”)

Posted on December 30, 2014 by Warren Woessner

I don’t think I can recall a more action-packed year for intellectual property law in my career, much less during the almost six years that I have been writing this blog. I am trying to write this while in transit, … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , , , , , , , , , | Leave a comment

Mayo Meet Alice Meet Myriad – Fed. Cir. Appreciates “Abstract Art”

Posted on December 18, 2014 by Warren Woessner

On December 20th, a panel of the Fed. Cir. of Judges Dyk, Clevinger and Prost – Dyk writing – found that six claims in Myriad’s dwindling arsenal of BRACA1 and 2 patents were invalid as claiming non-statutory subject matter. (University … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , , , , , | 2 Comments